NEW YORK (360Dx) – DiaSorin Inc. and Meridian Bioscience have entered into a strategic collaboration to sell DiaSorin's Helicobacter pylori stool antigen test for use on DiaSorin's Liaison platform, they announced after the close of the market on Tuesday.
The test, which detects H. Pylori, will be sold under the Meridian brand name worldwide. DiaSorin Inc., based in Minnesota, is a subsidiary of Italian firm DiaSorin S.p.A.
DiaSorin and Meridian Bio will collaborate on sales and marketing efforts aimed at hospitals and reference labs in the US, and Meridian Bio, headquartered in Cincinnati, will receive royalties on sales of the Liaison H. pylori stool antigen test in the US and the UK, as well as royalties received under a previous deal.
In July 2010, DiaSorin and Meridian Bio entered into an agreement under which DiaSorin would use Meridian Bio's technology to develop a gastrointestinal panel for use on the Liaison and Liaison XL platforms.
The partners said that the new collaboration will result in the termination of all pending legal disputes and expand the scope of the earlier agreement. DiaSorin and Meridian Bio have also outlined a framework to partner on the development of other stool-based tests for use on the Liaison system.
Additional terms were not disclosed.
"This collaboration creates synergies between state-of-the-art products and technology, which will result in expanded access to a fully automated test for the detection of H. pylori antigen in stool," DiaSorin CEO Carlo Rosa said in a statement." Moreover, I'm confident that DiaSorin and Meridian will be able to develop additional stool-based tests, leveraging a reliable technology, a broad menu offer for the clients, and a large chemiluminescent platform installed base worldwide."